Clinical trial
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With…
NCT00055432 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00055432 |
|---|---|
| Title | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Gemzar and Alimta |
| First posted | Mar 4, 2003 |
| Last update posted | Sep 15, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: